Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03173092 | A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | terminated | Phase 4 | 141 | TakedaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT02618109 | Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia(LABMI) | terminated | Phase 4 | 119 | University Hospital, AngersOTHER_GOV | 1 | Oct 3, 2022 |
| clinicaltrials |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma(Velcadito) | terminated | Phase 4 | 24 | Basque Health ServiceOTHER_GOV | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01271010 | A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status | terminated | Phase 4 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 4, 2026source: clinicaltrials